Cargando…

Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma

Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for...

Descripción completa

Detalles Bibliográficos
Autores principales: Gera, Shweta, Ettel, Mark, Acosta-Gonzalez, Gabriel, Xu, Ruliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332419/
https://www.ncbi.nlm.nih.gov/pubmed/28293379
http://dx.doi.org/10.4254/wjh.v9.i6.300
_version_ 1782511537480531968
author Gera, Shweta
Ettel, Mark
Acosta-Gonzalez, Gabriel
Xu, Ruliang
author_facet Gera, Shweta
Ettel, Mark
Acosta-Gonzalez, Gabriel
Xu, Ruliang
author_sort Gera, Shweta
collection PubMed
description Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities.
format Online
Article
Text
id pubmed-5332419
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-53324192017-03-14 Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma Gera, Shweta Ettel, Mark Acosta-Gonzalez, Gabriel Xu, Ruliang World J Hepatol Minireviews Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities. Baishideng Publishing Group Inc 2017-02-28 2017-02-28 /pmc/articles/PMC5332419/ /pubmed/28293379 http://dx.doi.org/10.4254/wjh.v9.i6.300 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Gera, Shweta
Ettel, Mark
Acosta-Gonzalez, Gabriel
Xu, Ruliang
Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma
title Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma
title_full Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma
title_fullStr Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma
title_full_unstemmed Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma
title_short Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma
title_sort clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332419/
https://www.ncbi.nlm.nih.gov/pubmed/28293379
http://dx.doi.org/10.4254/wjh.v9.i6.300
work_keys_str_mv AT gerashweta clinicalfeatureshistologyandhistogenesisofcombinedhepatocellularcholangiocarcinoma
AT ettelmark clinicalfeatureshistologyandhistogenesisofcombinedhepatocellularcholangiocarcinoma
AT acostagonzalezgabriel clinicalfeatureshistologyandhistogenesisofcombinedhepatocellularcholangiocarcinoma
AT xuruliang clinicalfeatureshistologyandhistogenesisofcombinedhepatocellularcholangiocarcinoma